Inherited progressive cardiac conduction disorders

Current Opinion in Cardiology

Volumn 30, Issue 1, 2015, Pages 33-39

  Baruteau, Alban Elouen ^a,b   Probst, Vincent ^a   Abriel, Hugues ^c  

^a INSERM   (France)

^b CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Arrhythmias; Atrio ventricular block; Electrophysiology; Genetics; Ion channels membrane transport

Indexed keywords

GAP JUNCTION PROTEIN; POTASSIUM CHANNEL KCNK17; SODIUM CHANNEL NAV1.5; SODIUM CHANNEL NAV1.8; TRANSCRIPTION FACTOR NKX2.5; TRANSCRIPTION FACTOR TBX5; TRANSIENT RECEPTOR POTENTIAL CHANNEL M4; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL BETA 1 SUBUNIT; CARDIOTONIC AGENT; NUCLEAR PROTEIN; T BOX TRANSCRIPTION FACTOR; T-BOX TRANSCRIPTION FACTOR 5; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR;

ARTIFICIAL HEART PACEMAKER; ATRIOVENTRICULAR BLOCK; CARDIAC CHANNELOPATHY; CARDIOVASCULAR MAGNETIC RESONANCE; CONGENITAL HEART DISEASE; FAMILY COUNSELING; FOLLOW UP; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; GENETIC IDENTIFICATION; GENETIC RISK; GENETIC SCREENING; GENETIC VARIABILITY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONDUCTION SYSTEM; HUMAN; MEDICATION THERAPY MANAGEMENT; PACEMAKER IMPLANTATION; PEDIGREE; PROGRESSIVE CARDIAC CONDUCTION DISORDER; REVIEW; SCN5A OVERLAP SYNDROME; ARRHYTHMIAS, CARDIAC; CONGENITAL MALFORMATION; DIAGNOSTIC IMAGING; DISEASE COURSE; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; INCIDENCE; MALE; MUTATION; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

ARRHYTHMIAS, CARDIAC; CARDIOTONIC AGENTS; DIAGNOSTIC IMAGING; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HEART CONDUCTION SYSTEM; HETEROZYGOTE; HUMANS; INCIDENCE; MALE; MUTATION; NUCLEAR PROTEINS; PEDIGREE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; T-BOX DOMAIN PROTEINS; TRANSCRIPTION FACTORS;

EID: 84918783533     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000134     Document Type: Review

References (61)

1. Dobrzynski H, Anderson RH, Atkinson A, et al. Structure, function and clinical relevance of the cardiac conduction system, including the atrioventricular ring and outflow tract tissues. Pharmacol Ther 2013; 139:260-288.
2. Gilbert-Barness E. Conduction defects/cardiomyopathies. Adv Pediatr 2014; 61:127-148.
3. Munshi NV. Gene regulatory networks in cardiac conduction system development. Circ Res 2012; 110:1525-1537.
4. Anderson RH, Yanni J, Boyett MR, et al. The anatomy of the cardiac conduction system. Clin Anat 2009; 22:99-113.
5. Gourdie RG, Harris BS, Bond J, et al. Development of the cardiac pacemaking and conduction system. Birth Defects Res C Embryo Today 2003; 69:46-57.
6. Yanni J, Boyett MR, Anderson RH, et al. The extent of the specialized atrioventricular ring tissues. Heart Rhythm 2009; 6:672-680.
7. Monfredi O, Dobrzynski H, Mondal T, et al. The anatomy and physiology of the sinoatrial node: a contemporary review. Pacing Clin Electrophysiol 2010; 33:1392-1406.
8. Nikolaidou T, Aslanidi OV, Zhang H, et al. Structure-function relationship in the sinus and atrioventricular nodes. Pediatr Cardiol 2012; 33:890-899.
9. Barbuti A, Baruscotti M, DiFrancesco D. The pacemaker current: from basics to the clinics. J Cardiovasc Electrophysiol 2007; 18:342-347.
10. Kleber AG, Rudy Y. Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiol Rev 2004; 84:431-488.
11. Lynch HT, Mohiuddin S, Sketch MH, et al. Hereditary progressive atrioventricular conduction defect. A new syndrome? JAMA 1973; 225:1465-1470.
12. Gazes PC, Culler RM, Taber E, et al. Congenital familial cardiac conduction defects. Circulation 1965; 32:32-34.
13. Schott JJ, Alshinawi C, Kyndt F, et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999; 23:20-21.
14. Watanabe H, Koopmann TT, Le SS, et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008; 118:2260-2268.
15. Gourraud JB, Kyndt F, Fouchard S, et al. Identification of a strong genetic background for progressive cardiac conduction defect by epidemiological approach. Heart 2012; 98:1305-1310.
16. Ambrosi A, Sonesson SE, Wahren-Herlenius M. Molecular mechanisms of congenital heart block. Exp Cell Res 2014; 325:2-9.
17. Baruteau AE, Fouchard S, Behaghel A, et al. Characteristics and long-term outcome of nonimmune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study. Eur Heart J 2012; 33:622-629.
18. Baruteau AE, Behaghel A, Fouchard S, et al. Parental electrocardiographic screening identifies a high degree of inheritance for congenital and childhood non-immune isolated atrio-ventricular block. Circulation 2012; 126:1469-1477.
19. Cannon BC, Ackerman MJ. Surprise, surprise: idiopathic, isolated complete atrioventricular block may be heritable. Circulation 2012; 126:1434-1435.
20. Abriel H. Cardiac sodium channel Nav1.5 and interacting proteins: physiology and pathophysiology. J Mol Cell Cardiol 2010; 48:2-11.
21. Remme CA. Cardiac sodium channelopathy associated with SCN5A mutations: electrophysiological, molecular and genetic aspects. J Physiol 2013; 591:4099-4116.
22. Kovach JR, Benson DW. Conduction disorders and Nav1.5. Cardiol Clin 2014; 6:723-731.
23. Zimmer T, Surber R. SCN5A channelopathies: an update on mutations and mechanisms. Prog Biophys Mol Biol 2008; 98:120-136.
24. Remme CA, Wilde AAM, Bezzina CR. Cardiac sodium channel overlap syndromes: different faces of SCN5A mutations. Trends Cardiovasc Med 2008; 18:78-87.
25. Kanter RJ, Pfeiffer R, Hu D, et al. Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation 2012; 125:14-22.
26. Kwon HW, Lee SY, Kwon BS, et al. Long QT syndrome and dilated cardiomyopathy with SCN5A p.R1193Q polymorphism: cardioverter-defibrillator implantation at 27 months. Pacing Clin Electrophysiol 2012; 35:e243-e246.
27. Olesen MS, Yuan L, Liang B, et al. High prevalence of long QT syndromeassociated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet 2012; 5:450-459.
28. Nakaya H. SCN5A mutations associated with overlap phenotype of long QT syndrome type 3 and Brugada syndrome. Circ J 2014; 78:1061-1062.
29. Hothi SS, Ara F, Timperley JP. Y1449C SCN5A mutation associated with overlap disorder comprising conduction disease, Brugada syndrome, and atrial flutter. J Cardiovasc Electrophysiol 2014. [Epub ahead of print]
30. Shy D, Gillet L, Abriel H. Cardiac sodium channel Nav1.5 distribution in myocytes via interacting proteins: the multiple pool model. Biochim Biophys Acta 2013; 1833:886-894.
31. Brackenbury WJ, Isom LL. Na+ channel β subunits: overachievers of the ion channel family. Front Pharmacol 2011; 2:53.
32. Pfeufer A, van NC, Marciante KD, et al. Genome-wide association study of PR interval. Nat Genet 2010; 42:153-159.
33. Bezzina CR, Barc J, Mizusawa Y, et al. Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet 2013; 45:1044-1049.
34. Verkerk AO, Remme CA, Schumacher CA, et al. Functional Nav1.8 channels in intracardiac neurons: the link between SCN10A and cardiac electrophysiology. Circ Res 2012; 111:333-343.
35. Yang T, Atack TC, Stroud DM, et al. Blocking SCN10A channels in heart reduces late sodium current and is antiarrhythmic. Circ Res 2012; 111:322-332.
36. van den Boogaard M, Smemo S, Burnicka-Turek O, et al. A common genetic variant within SCN10A modulates cardiac SCN5A expression. J Clin Invest 2014; 124:1844-1852.
37. Hu D, Barajas-Martinez H, Pfeiffer R, et al. Mutations in SCN10A are responsible for a large fraction of cases of Brugada syndrome. J Am Coll Cardiol 2014; 64:66-79.
38. Temple IP, Inada S, Dobrzynski H, et al. Connexins and the atrioventricular node. Heart Rhythm 2013; 10:297-304.
39. Makita N, Seki A, Sumitomo N, et al. A connexin40 mutation associated with a malignant variant of progressive familial heart block type I. Circ Arrhythm Electrophysiol 2012; 5:163-172.
40. Abriel H, Syam N, Sottas V, et al. TRPM4 channels in the cardiovascular system: physiology, pathophysiology, and pharmacology. Biochem Pharmacol 2012; 84:873-881.
41. Kruse M, Schulze-Bahr E, Corfield V, et al. Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I. J Clin Invest 2009; 119:2737-2744.
42. Liu H, El ZL, Kruse M, et al. Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease. Circ Cardiovasc Genet 2010; 3:374-385.
43. Stallmeyer B, Zumhagen S, Denjoy I, et al. Mutational spectrum in the Ca(2+) activated cation channel gene TRPM4 in patients with cardiac conductance disturbances. Hum Mutat 2011; 33:109-117.
44. Friedrich C, Rinne S, Zumhagen S, et al. Gain-of-function mutation in TASK-4 channels and severe cardiac conduction disorder. EMBO Mol Med 2014; 6:937-951.
45. Bruneau BG. The developmental genetics of congenital heart disease. Nature 2008; 451:943-948.
46. Zaidi S, Choi M, Wakimoto H, et al. De novo mutations in histone-modifying genes in congenital heart disease. Nature 2013; 498:220-223.
47. Bruneau BG, Srivastava D. Congenital heart disease: entering a new era of human genetics. Circ Res 2014; 114:598-599.
48. Moskowitz IP, Kim JB, Moore ML, et al. A molecular pathway including Id2, Tb×5, and Nk×2-5 required for cardiac conduction system development. Cell 2007; 129:1365-1376.
49. Sizarov A, Devalla HD, Anderson RH, et al. Molecular analysis of patterning of conduction tissues in the developing human heart. Circ Arrhythm Electrophysiol 2011; 4:532-542.
50. McCulley DJ, Black BL. Transcription factor pathways and congenital heart disease. Curr Top Dev Biol 2012; 100:253-277.
51. Schott JJ, Benson DW, Basson CT, et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 1998; 281:108-111.
52. McElhinney DB, Geiger E, Blinder J, et al. NKX2.5 mutations in patients with congenital heart disease. J Am Coll Cardiol 2003; 42:1650-1655.
53. Ouyang P, Saarel E, Bai Y, et al. A de novo mutation in NKX2.5 associated with atrial septal defects, ventricular noncompaction, syncope and sudden death. Clin Chim Acta 2011; 412:170-175.
54. Guntheroth W, Chun L, Patton KK, et al. Wenckebach periodicity at rest that normalizes with tachycardia in a family with a NKX2.5 mutation. Am J Cardiol 2012; 110:1646-1650.
55. Nakashima Y, Yanez DA, Touma M, et al. Nk×2-5 suppresses the proliferation of atrial myocytes and conduction system. Circ Res 2014; 114:1103-1113.
56. Basson CT, Bachinsky DR, Lin RC, et al. Mutations in human TBX5 [corrected] cause limb and cardiac malformation in Holt-Oram syndrome. Nat Genet 1997; 15:30-35.
57. Baban A, Pitto L, Pulignani S, et al. Holt-Oram syndrome with intermediate atrioventricular canal defect, and aortic coarctation: functional characterization of a de novo TBX5 mutation. Am J Med Genet A 2014; 164A:1419-1424.
58. McDermott DA, Fong JC, Basson CT. Holt-Oram syndrome. In Pagon RA, Heal AMA, editors. GeneReviews [Internet]. Seattle, WA: University of Washington; 1993. Available from: http://www.ncbi.nlm.nih.gov/books/NBK1111/.
59. Bogarapu S, Bleyl SB, Calhoun A, et al. Phenotype of a patient with contiguous deletion of TBX5 and TBX3: expanding the disease spectrum. Am J Med Genet A 2014; 164A:1304-1309.
60. Ackerman MJ, Priori SG, Willems S, et al. HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies. Europace 2011; 13:1077-1109.
61. Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF AHA, PACES, and AEPC in June 2013. Heart Rhythm 2013; 10:1932-1963.